Drug Type Autologous CAR-T |
Synonyms T 60c, T-60c |
Target |
Action modulators |
Mechanism Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | - | 01 Oct 2023 | |
| Colorectal Cancer | Phase 2 | - | 01 Oct 2023 | |
| Endometrial Carcinoma | Phase 2 | - | 01 Oct 2023 | |
| ER positive, PR positive, HER2 positive breast cancer | Phase 2 | - | 01 Oct 2023 | |
| Esophageal Carcinoma | Phase 2 | - | 01 Oct 2023 | |
| Non-Small Cell Lung Cancer | Phase 2 | - | 01 Oct 2023 | |
| Ovarian Cancer | Phase 2 | - | 01 Oct 2023 | |
| Pancreatic Cancer | Phase 2 | - | 01 Oct 2023 | |
| Prostatic Cancer | Phase 2 | - | 01 Oct 2023 | |
| Stomach Cancer | Phase 2 | - | 01 Oct 2023 |





